Sarda Proteins will convene its Board of Directors on Wednesday, August 05, 2026, to deliberate on strategic capital structure adjustments. The primary agenda item involves considering proposals for raising funds through the issuance of equity shares, convertible bonds, debentures, convertible warrants, preference shares, or other equity-linked securities. This move signals the company’s intent to evaluate multiple avenues for capital infusion, potentially impacting shareholder equity and future operational capacity.

The board meeting was notified pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted to the General Manager – Listing Compliance at BSE Limited, located in Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001. The company’s scrip code on the exchange is 519242.

The scope of the proposed fundraising is broad, encompassing any method permitted under applicable laws. Specifically, the company may proceed with a rights issue, private placement, preferential issue, or qualified institutions placement (QIP). These modes are governed by the Companies Act, 2013, read with the rules notified thereunder, and the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018.

Key Agenda Items

The board’s deliberations will focus on the following key areas:

Shirish Dhirajlal Savaliya, Managing Director of Sarda Proteins Limited (DIN: 08721554), signed the intimation letter on behalf of the Board of Directors. The notice also included provision for "any other items with the permission of chairperson," allowing for additional business to be transacted if deemed necessary during the session.

What This Means for Investors

The decision to explore diverse fundraising instruments indicates a proactive approach to capital management. By keeping options open for both debt (convertible bonds, debentures) and equity (shares, warrants), the company retains flexibility in choosing the most cost-effective and strategically appropriate method based on prevailing market conditions. Shareholders should monitor subsequent filings for specific details regarding the quantum of funds sought, pricing mechanisms, and the final instrument selected, which will determine the immediate impact on shareholding patterns and valuation.

Shareholders of Sarda Proteins Limited approved a strategic rebranding and significant capital expansion during an Extra-Ordinary General Meeting (EGM) held on July 30, 2026. The key resolution saw members approve the change of the company’s name from Sarda Proteins Limited to Fresita Proteins Limited, subject to statutory and regulatory approvals. This move aligns with the company’s proposed future business activities and expansion plans, as reflected in the concurrent approval to alter the Main Object Clause of the Memorandum of Association.

The meeting, conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM) in compliance with Ministry of Corporate Affairs circulars and SEBI Listing Regulations, commenced at 11:00 A.M. (IST) and concluded at 11:21 A.M. (IST). Yagnik Arvindbhai Satasiya served as Chairperson of the meeting. CS Dharmik Solanki, Advisor to the Company, confirmed that the requisite quorum was present throughout the proceedings.

Beyond the name change, shareholders approved a substantial increase in the Authorized Share Capital from ₹13,00,00,000 (Rupees Thirteen Crore Only) to ₹1,00,00,00,000 (Rupees One Hundred Crore Only). This capital hike requires consequential alterations to Clause V of the Memorandum of Association. The company had already secured Name Availability Approval from the Central Registration Centre (CRC), Ministry of Corporate Affairs, for the proposed name "Fresita Proteins Limited". A certificate from the Statutory Chartered Accountant confirming compliance with Regulation 45 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 was also placed on record.

Board Appointments and Regularizations

The EGM addressed several critical governance matters, including the regularization and appointment of key board members:

Shirish Dhirajlal Savaliya, Managing Director of the company, signed the submission to the BSE Limited. The appointments aim to strengthen the board’s oversight capabilities as the company transitions under its new identity.

Auditor Appointments

Members also approved the appointment of Statutory Auditors to fill a casual vacancy. Additionally, the shareholders authorized the appointment of Statutory Auditors for a first term of five consecutive years, commencing from April 1, 2026, and ending on March 31, 2031. This long-term tenure provides continuity in financial oversight during the company’s restructuring phase.

What the Numbers Show

The decision to increase authorized share capital by nearly eight times — from ₹13 crore to ₹100 crore — signals Sarda Proteins’ intent to raise fresh equity or issue convertible instruments in the future without repeated shareholder approvals for minor increments. Combined with the name change to Fresita Proteins, these moves suggest a comprehensive strategic reset aimed at attracting new investors and expanding into new business verticals as outlined in the altered Main Object Clause.